Price
Target price
€2.21
€2.21
-2.200%
-0.05
-2.200%
-
27.09.24 / Tradegate
WKN: 520394 / Name: B.R.A.I.N. Biotechnology / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock B.R.A.I.N. Biotechnology Research and Information Network AG is only available for our menbers.
Not a member yet? Sign up for free!
Not a member yet? Sign up for free!
Financial data and news for B.R.A.I.N. Biotechnology
sharewise wants to provide you with the best news and tools for B.R.A.I.N. Biotechnology, so we directly link to the best financial data sources.
Financials
News
EQS-News: BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
EQS-News: BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
EQS-Adhoc: BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma
EQS-Adhoc: BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma
EQS-News: BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year
EQS-News: BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year
EQS-News: BRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes
EQS-News: BRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes
EQS-News: BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets
EQS-News: BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets
EQS-News: BRAIN Biotech AG takes next step to optimize group structure
EQS-News: BRAIN Biotech AG takes next step to optimize group structure